Australia - English - Department of Health (Therapeutic Goods Administration)

idt australia ltd - doxazosin mesilate, quantity: 9.704 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; indigo carmine aluminium lake; pregelatinised maize starch; iron oxide yellow; magnesium stearate - benign prostatic hyperplasia: for the treatment of both the urinary outflow obstruction and obstuctive and irritative symptoms associated with bph. hypertension: for the treatment of hypertension, either alone or in combination with diuretics, beta-adrenergic blocking agents, calcium chanel blockers, or angiotensin-converting enzyme inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

idt australia ltd - doxazosin mesilate, quantity: 4.852 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide red; microcrystalline cellulose; iron oxide yellow; pregelatinised maize starch; magnesium stearate - benign prostatic hyperplasia: for the treatment of both the urinary outflow obstruction and obstuctive and irritative symptoms associated with bph. hypertension: for the treatment of hypertension, either alone or in combination with diuretics, beta-adrenergic blocking agents, calcium chanel blockers, or angiotensin-converting enzyme inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

idt australia ltd - doxazosin mesilate, quantity: 2.426 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; iron oxide yellow - benign prostatic hyperplasia: for the treatment of both the urinary outflow obstruction and obstuctive and irritative symptoms associated with bph. hypertension: for the treatment of hypertension, either alone or in combination with diuretics, beta-adrenergic blocking agents, calcium chanel blockers, or angiotensin-converting enzyme inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

idt australia ltd - doxazosin mesilate, quantity: 1.213 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; magnesium stearate - benign prostatic hyperplasia: for the treatment of both the urinary outflow obstruction and obstuctive and irritative symptoms associated with bph. hypertension: for the treatment of hypertension, either alone or in combination with diuretics, beta-adrenergic blocking agents, calcium chanel blockers, or angiotensin-converting enzyme inhibitors

United States - English - NLM (National Library of Medicine)

kv pharmaceuticals - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - tablet - 1 mg - a. benign prostatic hyperplasia (bph) doxazosin mesylate tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin mesylate tablets may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin mesylate tablet monotherapy. doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. b. hypertension doxazosin mesylate tablets are also indicated for the treatment of hypertension. doxazosin mesylate tablets may be

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - doxazosin mesilate - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - doxazosin mesilate - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - doxazosin mesilate - oral tablet - 4mg

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, llc - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerou

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerou